NCT02576002 - Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension) | Biotech Hunter

Enrollment

2,691

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions

Hypertension, Pulmonary

Interventions

DRUG

Assigned pulmonary hypertension medication

As assigned by treating physician; may include following product classes: - Calcium channel blockers/antagonists - Prostanoids (prostaglandins, thromboxanes, prostacyclines) - Endothelin receptor antagonists - PDE-5 inhibitors - SGc stimulators

Trial Locations (1)

Unknown

Boston